Showing: 1 - 3 of 3 RESULTS

Natural History of Kids’ Benign Bone Tumors; Sarcoma Staging; Pathologic Fractures

Almost 20% of asymptomatic children and adolescents had benign bone tumors of the extremities, a review of a longitudinal radiographic collection showed.

Overall, 35 benign tumors were identified in 33 pediatric patients whose median age was 8. The most commonly identified tumor types were non-ossifying fibromas (NOF, 7.5%), enostoses (5.2%), osteochondromas (4.5%), and enchondromas (1.8%).

The findings came from a review of the Brush Inquiry, a collection of 25,555 radiographs and 262 healthy children. The x-rays were all left-sided views of each patient’s upper and lower extremities. The overall incidence of benign tumors in the asymptomatic population was 18.9%, and the median age at detection after a previous negative radiograph was 9 years. NOFs were the only tumor type that resolved over time, Christopher D. Collier, MD, of the University of Chicago, reported during the Musculoskeletal Tumor Society (MSTS) virtual meeting.

“The goal of this study was to give us more accurate information on the overall incidence of these [tumors] and the natural history,” MSTS program co-chair Thomas J. Scharschmidt, MD, of Ohio State University in Columbus, said during a review of selected abstracts. “The impetus for the study is that those of us in the oncology world have a lot of consults for NOFs, osteochondromas, and other things that can cause a lot of anxiety for families. This information provides us with some numbers to be able to counsel families when they are sent to us.”

Following are summaries of two other abstracts from the meeting.

Skeletal Staging in Bone Sarcomas

As many as 35% of patients with bone sarcomas and bony metastases at diagnosis would have gone undetected if staging had included only a CT scan of the lungs, a separate review of 9,855 patients showed.

The analysis of the National Cancer Database included patients with newly diagnosed bone sarcomas during 2010-2015: 4,013 patients with chondrosarcoma, 4,105 with osteosarcoma, and 1,737 with Ewing sarcoma. The data showed that 11.7% of patients had lung metastases and 4.8% had bone metastases at diagnosis. The presence of bone metastases was associated with worse survival in each of the three histologies and in all histologies combined (P<0.01).

The study had its origin in the growing interest in modified staging protocols that challenge the value of skeletal staging, Collier and colleagues noted in a poster presentation. The data showed that lung-only staging would have missed metastatic disease in 16% of patients with osteosarcoma, 25% of those with chondrosarcoma, and 35% of patients with Ewing sarcoma.

“I think we probably routinely get bone staging, more so in our bone sarcomas and soft-tissue sarcomas, but I think this study really highlighted the importance of that as well as the poor outcomes with bone metastases overall across all of these bone sarcomas,” said Scharschmidt.

Pathologic Fracture and Limb Salvage Outcomes

Pathologic fracture did not adversely affect patient or implant survival following limb salvage surgery for osteosarcoma, a review of 304 cases showed.

During a median follow-up of 13 years, 17 (5.6%) patients had a

Risky Breast Lumps; Bone Testing Lags in Prostate Cancer; Cancer Breathalyzer?

Benign breast lesions detected after a woman’s initial screening mammogram are more likely to become malignant. (European Breast Cancer Conference)

Younger adults who have never smoked are the group with the biggest increase in use of electronic cigarettes. (American Cancer Society, American Journal of Preventive Medicine)

The FDA issued draft guidance aimed at getting more premenopausal women enrolled in clinical trials of new drugs and biologic agents for breast cancer.

Only one-fourth of men with prostate cancer had testing for bone health and integrity after androgen deprivation therapy, which causes loss of bone mineral. (Journal of the National Comprehensive Cancer Network)

Updated results from a randomized trial supported single-agent nivolumab (Opdivo), as opposed to nivolumab-ipilimumab (Yervoy) combination therapy, as adjuvant therapy for resected melanoma, and adding nivolumab to neoadjuvant chemotherapy significantly improved pathologic complete response in resectable non-small cell lung cancer, Bristol Myers Squibb announced in separate statements.

Amgen announced that its investigational KRAS inhibitor sotorasib met the primary endpoint of objective response in a phase II clinical trial of previously treated advanced non-small cell lung cancer.

Minority patients with cancer, as compared with white patients, show increased risk of coronavirus infection, higher rates of hospitalization for COVID-19, and lower use of telehealth during the ongoing pandemic. (ASCO Quality Care Symposium)

Introduction of a pay-for-performance program in oncology practices increased prescriptions for cancer drugs supported by high-quality clinical evidence without significantly increasing the total cost of cancer care. (Penn Medicine, Journal of Clinical Oncology)

More than 100 patient organizations worldwide have formed the World Patients Alliance to increase patient involvement in shaping healthcare policy.

Surgery for benign breast disease does not interfere with breastfeeding. (American College of Surgeons)

Within a week after infusion of CAR T-cell therapy, changes in circulating DNA may identify which patients with large B-cell lymphoma will benefit from the treatment. (University of Texas MD Anderson Cancer Center)

Immune checkpoint inhibitors used to treat multiple types of cancer may aggravate systemic inflammation that drives the development of coronary atherosclerosis. (JACC: CardioOncology)

A rapid and inexpensive breath test showed promise for head and neck cancer. (Flinders University, British Journal of Cancer)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Source Article

Police Probe Pioneering Hip Surgeon Over Bone Hoarding Claims

Police are investigating claims that a renowned surgeon may have kept thousands of bones from patients he operated on.

Derek McMinn, referred to on his website as the ‘father of modern hip resurfacing’, was responsible for a type of surgery that helped former world number one tennis player Sir Andy Murray return to topflight competition.

Mr McMinn has since been suspended from Edgbaston Hospital in Birmingham.

The Independent reported that he allegedly kept the bones of at least 5224 of his patients over a quarter of a century.

Hospital owner, Circle Health Group, said it took the matter “incredibly seriously”.

Investigation Under Human Tissue Law

It is understood that West Mercia Police are investigating an allegation of Breach of Statutory Licensing requirements under the Human Tissue Act 2004. Under the law, it may be an offence to store human tissue for certain purposes without a licence.

The inquiry was launched after referral by the Human Tissue Authority (HTA).

An HTA spokesperson confirmed that it carried out an investigation after concerns were raised by previous hospital owners BMI Healthcare in August 2019, and by the Care Quality Commission following an inspection.

The HTA said its own investigation involved BMI Healthcare staff, as well as Mr McMinn.

The Authority said it was unable to comment further as the matter was now the subject of a police investigation.

The General Medical Council (GMC) said it was “aware of concerns” and had asked BMI Healthcare to send investigation reports and other relevant evidence.

A GMC spokesperson said: “We can and will take action where there is evidence that a doctor poses a risk to patients or public confidence in the profession.”

The GMC confirmed that Mr McMinn was currently registered with a licence to practise.

‘No Stone Unturned’

A spokesperson for Circle Health Group said: “We only acquired the hospital in June and we will leave no stone unturned in investigating these historic issues: they have all been reported to the appropriate authorities and we will co-operate closely with regulators to resolve them.”

The spokesperson confirmed that Mr McMinn’s contract with the Edgbaston hospital had been terminated.

According to Mr McMinn’s website, he graduated from St Thomas’ Hospital in London, and is one of the globe’s leading hip and knee experts, and the inventor of the Birmingham Hip Resurfacing technique.

He has performed more than 3500 hip resurfacings and over 6000 total hip replacements.

He is said to have developed an alternative treatment to hip replacement after seeing poor results in young people.

Source Article